Ahmet Rukie Ana Maria, Nascu Andrei Gabriel, Camen Georgiana Cristina, Obleaga Cosmin Vasile, Popa Dragos George, Mirea Cecil Sorin
Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Department of Informatics, Faculty of Science, University of Craiova, 200585 Craiova, Romania.
Diagnostics (Basel). 2025 Aug 25;15(17):2147. doi: 10.3390/diagnostics15172147.
Breast cancer is the most common malignancy affecting women worldwide and continues to pose significant challenges despite progress in early detection and personalized therapies. While its pathogenesis has traditionally been associated with genetic, hormonal, and environmental factors, recent studies have highlighted the potential role of dysbiosis-an imbalance in gut and systemic microbiota-in breast cancer development and progression. This article aims to examine the mechanisms through which systemic dysbiosis may contribute to breast cancer risk and explore its therapeutic implications. This study seeks to analyze and compare the fecal microbiota profiles of breast cancer patients and healthy individuals from a single center in Craiova, Romania, in order to identify microbial signatures linked to breast cancer and BRCA mutation status. Special attention is given to the gut-liver axis and its influence on estrogen circulation, a key factor in hormone-sensitive breast cancers. Evidence suggests that dysbiosis can influence breast cancer progression by promoting chronic inflammation, impairing immune regulation, and altering estrogen metabolism through the gut-liver axis. These effects may contribute to tumor development, immune evasion, and therapeutic resistance. Interventions aimed at restoring microbial balance show promise in preclinical studies for mitigating these effects. Systemic dysbiosis represents a potentially modifiable risk factor in breast cancer. Microbiota profiling may serve as a useful biomarker for risk stratification and therapeutic response. Future research into microbiome-based interventions could offer novel approaches for prevention and treatment in breast cancer care.
乳腺癌是全球影响女性的最常见恶性肿瘤，尽管在早期检测和个性化治疗方面取得了进展，但仍继续构成重大挑战。虽然其发病机制传统上与遗传、激素和环境因素有关，但最近的研究强调了生态失调（肠道和全身微生物群的失衡）在乳腺癌发生和发展中的潜在作用。本文旨在研究全身生态失调可能导致乳腺癌风险的机制，并探讨其治疗意义。本研究旨在分析和比较罗马尼亚克拉约瓦一个单一中心的乳腺癌患者和健康个体的粪便微生物群谱，以确定与乳腺癌和BRCA突变状态相关的微生物特征。特别关注肠-肝轴及其对雌激素循环的影响，雌激素循环是激素敏感性乳腺癌的一个关键因素。有证据表明，生态失调可通过促进慢性炎症、损害免疫调节以及通过肠-肝轴改变雌激素代谢来影响乳腺癌进展。这些影响可能有助于肿瘤发展、免疫逃逸和治疗耐药性。旨在恢复微生物平衡的干预措施在临床前研究中显示出减轻这些影响的前景。全身生态失调是乳腺癌中一个潜在可改变的风险因素。微生物群分析可作为风险分层和治疗反应的有用生物标志物。未来对基于微生物组的干预措施的研究可为乳腺癌护理的预防和治疗提供新方法。
